AEON Biopharma amends warrant terms, cuts exercise price to $0.20

AEON Biopharma entered into an amendment to its two-year milestone warrants on November 2, 2026, reached with holders who together held at least 67% of the shares of common stock and pre-funded warrants issuable under the company's outstanding two-year milestone warrants, which had been issued on July 15, 2026.¹

The two-year warrants can be exercised for shares of AEON's Class A common stock or, instead, for pre-funded warrants to buy that common stock.¹ Under the amendment, effective the same day, the exercise price was lowered from $0.3221 to $0.20 per share of common stock, and from $0.3220 to $0.1999 per pre-funded warrant.¹ Some warrant holders have agreed to exercise their warrants at the new, lower price, and the company expects to collect roughly $6.2 million in gross proceeds from those exercises.¹

Because of a contractual term in the original warrants, the amended price applies to all outstanding two-year warrants, including those held by parties who did not sign the amendment.¹ Apart from the price change, the warrants' other terms, including how many shares or pre-funded warrants can be obtained on exercise and when they expire, stay the same.¹ AEON reported 71,517,020 shares of its common stock outstanding as of October 30, 2026.¹

The repricing follows an earlier trigger event: on September 30, 2026, AEON said it had gotten Type 2b meeting minutes from the FDA indicating no obstacle to moving its product ABP-450 forward toward a Biologics License Application filed under the Section 351(k) biosimilar route, which under the warrants' terms set off their accelerated expiration.¹ The two-year warrants are now set to expire on November 16, 2026.¹